| Literature DB >> 23816278 |
Patrick Boruett1, Dorine Kagai, Susan Njogo, Peter Nguhiu, Christine Awuor, Lillian Gitau, John Chalker, Dennis Ross-Degnan, Rolf Wahlström, Göran Tomson.
Abstract
BACKGROUND: Achieving high rates of adherence to antiretroviral therapy (ART) in resource-poor settings comprises serious, but different, challenges in both the first months of treatment and during the life-long maintenance phase. We measured the impact of a health system-oriented, facility-based intervention to improve clinic attendance and patient adherence.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23816278 PMCID: PMC3704969 DOI: 10.1186/1472-6963-13-242
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Summary of patients’ demographic and clinical characteristics
| Female (n = 1258) | 289 (64.8%) | 248 (70.5%) | 0.0908 | 337 (64.8%) | 384 (66.7%) | 0.5171 |
| Mean age (95% CI) | 39.4 (38.3–40.5) | 38 (37.1–38.9) | 0.065 | 38.6 (37.7–39.5) | 39.2 (38.4–40.1) | 0.349 |
| Single | 72 (16.1%) | 43 (12.2%) | 0.1157 | 79 (15.2%) | 79 (13.7%) | 0.1987 |
| Divorced/Widowed | 119 (26.7%) | 114 (32.4%) | 140 (26.9%) | 186 (32.3%) | ||
| Married | 181 (40.6%) | 159 (45.2%) | 253 (48.7%) | 268 (46.5%) | ||
| Male | 58.5 (56.7,60.3) | 58.3 (56.8,59.9) | 0.8974 | |||
| Female | 54.8 (53.5,56.0) | 55 (53.9,56.1) | 0.796 | 52.3 (51.1,53.5) | 52.8 (51.7,53.8) | 0.5529 |
| Stage 1 | ||||||
| Stage 2 | ||||||
| Stage 3 | ||||||
| Stage 4 | ||||||
| CD4 value | ||||||
| Adherence counselling | ||||||
*Missing data: marital status n = 201; WHO staging n = 180; initial CD4 n = 470; initial adherence counseling n = 3.
NB: Figures in bold show significant differences.
Figure 1Percentage visits kept or attended before appointment for experienced patients.
Figure 2Average % of visits kept within 3 days for experienced patients.
Figure 3Percentage visits with medication gap of more than 14 days for experienced patients.
Estimated changes in appointment keeping and medication gaps resulting from the intervention among experienced and newly treated patients
| Cohort | Group | Coefficient (± 95% CI) | p-value | Coefficient (± 95% CI) | p-value | Coefficient (± 95% CI) | p-value | |
| Exp. | Intervention | -0.25 (-0.54, 0.04) | 0.096 | |||||
| Control | 0.12 (-0.21, 0.45) | 0.485 | -2.78 (-7.72, 2.15) | 0.268 | 0.64 (-0.05, 1.34) | 0.071 | ||
| Difference | 0.48 (-1.29, 0.33) | 0.248 | ||||||
| New | Intervention | -0.14 (-0.72, 0.43) | 0.622 | -0.44 (-1.39, 0.51) | 0.365 | |||
| Control | 0.08 (-0.45, 0.61) | 0.769 | -1.8 (-9.84, 6.23) | 0.660 | 0.85 (-0.16, 1.85) | 0.100 | ||
| Difference | -0.72 (-1.7, 0.26) | 0.147 | -1.23 (-0.31, 2.76) | 0.117 | ||||
| Exp. | Intervention | -0.18 (-0.38, 0.01) | 0.064 | |||||
| Control | 0.31 (-0.15, 0.76) | 0.186 | 0.49 (-5.41, 6.4) | 0.870 | -0.12 (-0.88, 0.65) | 0.765 | ||
| Difference | ||||||||
| New | Intervention | 0.23 (-0.44, 0.89) | 0.503 | 2.68 (-5.34, 10.69) | 0.513 | 0.02 (-1.35, 1.4) | 0.973 | |
| Control | 0.23 (-0.12, 0.58) | 0.194 | -1.13 (-9.68, 7.43) | 0.796 | 0.11 (-0.86, 1.08) | 0.823 | ||
| Difference | -0.27 (-0.87, 0.33) | 0.374 | 7.85 (-17.16, 1.45) | 0.098 | -0.31 (-0.8, 1.42) | 0.585 | ||
| Exp. | Intervention | -0.15 (-0.62, 0.32) | 0.523 | -11.3 (-22.72, 0.07) | 0.051 | 0.18 (-1.09, 1.46) | 0.778 | |
| Control | -0.48 (-0.94, -0.02) | 0.041 | -0.68 (-6.03, 4.66) | 0.802 | 0.13 (-0.62, 0.87) | 0.739 | ||
| Difference | 0.33 (-0.37, 1.02) | 0.355 | -10.64 (-22.62, 1.33) | 0.081 | 0.06 (-1.22, 1.34) | 0.931 | ||
| New | Intervention | -0.37 (-1.42, 0.67) | 0.484 | -8.24 (-19.13, 2.65) | 0.138 | 0.9 (-0.52, 2.32) | 0.212 | |
| Control | 0.05 (-0.44, 0.54) | 0.830 | -3.87 (-12.43, 4.69) | 0.376 | 0.14 (-1.15, 1.42) | 0.833 | ||
| Difference | -0.43 (-1.75, 0.90) | 0.529 | -4.37 (-17.6, 8.86) | 0.517 | 0.77 (-1.15, 2.68) | 0.434 | ||
Exp. = Experienced patients, New = Newly treated patients; Figures in bold show significant differences between intervention and control group.
Figure 4Difference in average % of visits kept within 3 days, experienced patients.